DiaMedica Therapeutics Inc’s filing revealed that its 10% Owner STAHLBERG JAN acquired Company’s shares for reported $1.73 million on Nov 19 ’25. In the deal valued at $7.21 per share,240,352 shares were bought. As a result of this transaction, STAHLBERG JAN now holds 8,375,092 shares worth roughly $63.4 million.
Then, STAHLBERG JAN bought 208,872 shares, generating $1,547,574 in total proceeds. Upon buying the shares at $7.41, the 10% Owner now owns 8,712,390 shares.
Before that, STAHLBERG JAN bought 182,882 shares. DiaMedica Therapeutics Inc shares valued at $1,234,618 were divested by the 10% Owner at a price of $6.75 per share. As a result of the transaction, STAHLBERG JAN now holds 8,134,740 shares, worth roughly $61.58 million.
A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. H.C. Wainwright began covering DMAC with “Buy” recommendation on October 07, 2024.
Price Performance Review of DMAC
On Friday, DiaMedica Therapeutics Inc [NASDAQ:DMAC] saw its stock fall -11.30% to $7.57. Over the last five days, the stock has lost -7.17%. DiaMedica Therapeutics Inc shares have risen nearly 40.80% since the year began. Nevertheless, the stocks have fallen -4.84% over the past one year.
How much short interest is there in DiaMedica Therapeutics Inc?
A steep rise in short interest was recorded in DiaMedica Therapeutics Inc stocks on 2025-12-31, dropping by -1.16 million shares to a total of 4.09 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 5.25 million shares. There was a decline of -28.36%, which implies that there is a negative sentiment for the stock.
